Open AccessResponse to inhaled ceftazidime in patients with non‐cystic fibrosis bronchiectasis and chronic bronchial infection unrelated to Pseudomonas aeruginosa
Author(s) -
Riveiro Vanessa,
Casal Ana,
ÁlvarezDobaño José M.,
Lourido Tamara,
SuárezArtime Pedro,
RodríguezGarcía Carlota,
Ferreiro Lucía,
Toubes María E.,
Valdés Luis
Publication year - 2022
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.13534
Subject(s) - ceftazidime , medicine , bronchiectasis , pseudomonas aeruginosa , cystic fibrosis , antibiotics , concomitant , inhalation , gastroenterology , microbiology and biotechnology , anesthesia , lung , bacteria , genetics , biology
Inhaled antibiotics reduce the frequency of exacerbations. The objective was to assess the efficacy of inhaled ceftazidime in patients with non‐cystic fibrosis bronchiectasis (NCFB) and concomitant chronic bronchial infection (CBI) caused by potentially pathogenic microorganisms (PPM) other than Pseudomonas aeruginosa (PA). Material and Method Quasi‐experimental study in 21 patients with exacerbations who developed CBI by a PPM other than PA. Results Bacterial infection was resolved in 85.7% patients. Rehospitalizations, length of hospital stay, moderate exacerbations and blood levels of CRP decreased significantly. In addition, SGRQ questionnaire also decreased more than 4 points in 57.1% of the patients. Conclusion The results suggest that inhaled ceftazidime in NCFB unrelated to PA is a plausible alternative to the standard therapies used in clinical practice.